Artificial intelligence is already reshaping how regulatory professionals work—but with opportunity comes responsibility.

In this episode of Cognitio, we bring you key insights from an ARCS webinar led by Kyle from GXP Vigilance, exploring how AI is being used across regulatory affairs, pharmacovigilance and quality environments, and what professionals need to understand to use it safely and effectively.

This is not a conversation about hype. It’s about real-world application in regulated environments, where accuracy, accountability and patient safety cannot be compromised.

• Why AI adoption is accelerating across the life sciences sector—and what that means for regulatory roles
• The biggest risks of using AI, including hallucinations, fabricated citations and data leakage
• The critical importance of human accountability in all AI-assisted outputs
• Practical guidance on acceptable vs unacceptable uses of AI in regulated settings
• How prompt engineering is evolving—and why it’s becoming a core professional skill
• The difference between public AI tools and enterprise-grade solutions
• What’s coming next in governance, policy and regulatory expectations for AI

AI is a powerful tool—but it is not a source of truth.

Human oversight remains essential. Regulatory professionals are still the final decision-makers and are accountable for all outputs.

Using AI safely requires discipline. This includes avoiding confidential data, validating outputs and understanding the limitations of large language models.

Prompting matters. The quality of input directly impacts the reliability of output, making structured prompting an increasingly valuable capability.

Governance is coming. Organisations will need clear frameworks, policies and controls as regulatory expectations evolve.

As AI becomes embedded in everyday workflows, regulatory professionals must strike a balance between efficiency and compliance.

Those who understand both the capabilities and limitations of AI will be better positioned to lead in a rapidly changing environment—one where professionalism, judgement and trust remain central.

ARCS Australia is the peak body for life sciences professionals, advancing capability across the sector through education, community and advocacy.

🎧 Follow Cognitio for more conversations shaping the future of the life sciences sector
🔗 Learn more at ARCS Australia

What you’ll hear in this episodeKey takeawaysWhy this mattersAbout ARCS Australia

This week on Top 3 with Tim, ARCS CEO Dr Tim Boyle shares the biggest updates shaping the ARCS community and Australia’s life sciences sector.

In this short update:
• Final call for 2026 ARCS Annual Conference early bird registrations
• ARCS announces its new partnership with the Australian Institute of Company Directors (AICD) and the upcoming LifeSciences Company Directors Course
• Highlights from a huge week of sector engagement, including the sold-out Leadership Summit with MAPA, Melbourne member networking, and the Monash University careers roadshow

Tim also looks ahead to International Clinical Trials Day on 20 May, where ARCS will host a free online symposium focused on governance, AI, digital informed consent and the future of clinical trials in Australia.

ARCS continues to champion professionalism, capability building and sector-wide connection across the full life sciences ecosystem.

Join the conversation. Join ARCS today.

How do we separate misinformation from meaningful public health signals, and what happens when digital intelligence is combined with clinical evidence?

In this episode of Cognitio, we explore how online sentiment, AI-powered surveillance and real-world healthcare data can work together to identify, investigate and validate emerging vaccine safety concerns.

Dr Gerardo Luis Dimaguila, Informatics Lead at the Murdoch Children’s Research Institute and Data Innovation Lead at the Centre for Health Analytics, introduces VaxPulse, a digital surveillance learning health system developed since 2021. Using AI, social listening and advanced analytics, VaxPulse monitors vaccine-related concerns and misinformation across online platforms, helping public health professionals detect early warning signs and better understand the information environment shaping vaccine confidence.

Aishwarya Shetty, epidemiologist and vaccine safety specialist at the Centre for Health Analytics, then demonstrates how these digital insights can be translated into rigorous epidemiological investigation. Using VaxPulse data identifying menstrual health concerns following COVID-19 vaccination, Aishwarya presents how large-scale GP syndromic surveillance and broader safety datasets were used to validate public concerns, assess risk and strengthen evidence-based communication.

Together, this episode explores:
• How AI and digital surveillance are reshaping pharmacovigilance
• The growing role of social media as an early signal detection tool
• How misinformation and genuine public concerns can be distinguished
• The integration of digital signals with GP and clinical datasets
• Why transparent, evidence-led communication is critical to vaccine trust

This episode is essential listening for professionals in pharmacovigilance, vaccine safety, epidemiology, regulatory affairs, public health and digital health innovation.

Cognitio is ARCS Australia’s platform for thought leadership, professional development and sector-wide dialogue across the life sciences ecosystem.

Join the conversation. Join ARCS today.

What does high performance really look like when it’s shaped by lived experience?

In this episode of Cognitio, we explore the intersection between professional capability and chronic illness—and how navigating personal health challenges can fundamentally shape resilience, leadership, and perspective in the life sciences sector.

Hosted by Anna Megalakakis from ARCS, this conversation brings together Mark Del Borgo from the Department of Pharmacology at Monash University and his PhD student Isabella Simon. Both are not only researchers, but also consumers of the healthcare system—offering a rare and powerful dual perspective from inside the science and the lived experience it ultimately serves.

From the realities of diagnosis and long-term treatment, to the unseen pressures of maintaining performance in high-demand roles, this discussion highlights what often sits beneath the surface in our workplaces and research environments.

It also raises important questions for the sector:
How do we better support high performers managing chronic conditions?
What does empathetic leadership look like in practice?
And how can lived experience strengthen—not limit—professional contribution?

This is a conversation about resilience, but also about understanding. About the human side of science, and the importance of creating environments where people can perform at their best—because they are supported, not despite their challenges.

• Living and working with chronic illness in life sciences
• The impact of diagnosis on career direction and ambition
• Navigating research, academia, and health simultaneously
• Empathy, leadership, and building high-performing teams
• The role of lived experience in shaping better science and outcomes

• Anna Megalakakis – ARCS
• Mark Del Borgo – Department of Pharmacology, Monash University
• Isabella Simon – PhD Candidate, Pharmacology

ARCS Australia is the peak body for the life sciences sector, supporting professionals across the full product lifecycle through education, professional development, and community.

Key Topics CoveredFeatured in this EpisodeAbout ARCS

What can elite sport teach us about leadership in the workplace?

In this episode of the Cognitio Podcast, Tim Boyle sits down with Tomek Szklarski, Head Coach of the Australian National Handball Team, to explore how high-performance sporting environments develop resilient leaders, build trust under pressure, and create cultures where teams thrive.

Drawing on his experience as both a professional athlete and national coach, Tomek shares practical lessons from elite team sport that translate directly into leadership, management and team development within professional environments.

Together, Tim and Tomek discuss:

• Why resilience matters more than talent in sustained high-performance environments
• The transition from peer leadership to formal leadership
• How trust is built, broken and rebuilt under pressure
• Why great leaders create capability rather than dependency
• The role of vulnerability and self-awareness in leadership
• Practical strategies for developing resilience in yourself and others

Whether you lead a team, manage stakeholders, or are looking to strengthen your own professional resilience, this episode offers valuable insights into what it takes to lead when the pressure is on.

Tomek Szklarski is Head Coach of the Australian National Handball Team and a former professional European handball player. He has represented Sydney University, New South Wales and Australia at elite levels of competition, and has played a key role in developing handball talent nationally. Tomek brings a unique perspective on leadership shaped by years of experience as both a player and coach in high-performance sporting environments.

About the Guest

What does it really mean to design healthcare with patients?

In this episode of the Cognitio Podcast, Georghien Wiley, ARCS Convener for the Patient Engagement Interest Area, leads a powerful and deeply personal discussion on patient co-creation.

Through real-world experiences, this episode explores the realities of navigating the healthcare system in Australia, particularly for patients and carers in regional settings. From access challenges and fragmented care to the often-overlooked role of carers, the conversation highlights critical gaps between system design and lived experience.

It also reframes a key idea for the life sciences sector:
Lived experience is not supplementary to evidence. It is a form of expertise that should shape how we design services, clinical trials and patient support programs.

Key themes explored include:
• The impact of fragmented and uncoordinated care
• The hidden burden and invisibility of carers
• Health literacy and communication challenges
• The importance of trust, equity and inclusion in co-design
• Moving beyond tokenistic engagement to meaningful partnership

This episode is essential listening for professionals across clinical research, regulatory affairs, medical affairs, pharmacovigilance and market access who are looking to embed patient-centred approaches into their work.

Cell and gene therapies such as CAR-T are transforming modern medicine, offering new treatment options for cancers and rare diseases. But getting these breakthrough therapies to patients is not straightforward.

In this episode of the Cognitio Podcast, Warwick Shaw from Johnson & Johnson explores how advanced therapies move from regulatory approval to reimbursement in Australia. The discussion examines the role of the Medical Services Advisory Committee (MSAC), the National Health Reform Agreement, and the complex coordination between federal and state governments that influences patient access.

The conversation also highlights the growing pipeline of cell and gene therapies, the use of outcomes-based reimbursement models, and the policy changes needed to ensure Australian patients can access these life-changing treatments sooner.

Three signals this week point to a sector at a turning point.

Australia’s life sciences industry is accelerating—with stronger local capability, growing global engagement, and a more coordinated national R&D strategy taking shape.

But there’s a critical question we need to address.

As we move toward a more economically driven innovation model, how do we ensure health and medical research remains grounded in patient outcomes—not just commercial return?

In this week’s Top 3, I cover:
• The Ambitious Australia R&D strategy—and what it means for our sector
• A major capability investment in clinical trials infrastructure here in Sydney
• Why international partnerships will define our next phase of growth

If we get the balance right, we have a real opportunity to strengthen both our sector and outcomes for patients.

In this episode of Cognitio, Tim Boyle speaks with Dr Natalie Anderson about the evolving regulatory landscape for non-animal models in pharmaceutical development.

We explore global reforms at the US FDA and European Medicines Agency, the application of the Three Rs, and how Australia’s TGA is responding to advances in organoids, organ-on-chip technologies and in silico modelling. The discussion covers regulatory acceptance pathways, policy shifts, funding challenges and what this means for sponsors and regulatory professionals.

A must-listen for those working in regulatory affairs, nonclinical development and health policy as science and regulation continue to evolve.

In this episode of Cognitio, ARCS CEO Tim Boyle explores the behavioural science behind leadership, compliance and decision-making in regulated environments.

Despite extensive training and detailed SOPs, deviations still occur. So what’s missing? This conversation dives into the psychology of identity-based leadership, the forgetting curve, grey zone decision-making, and how culture shapes compliance in clinical research, regulatory affairs and life sciences.

If you work in clinical trials, medical affairs, pharmacovigilance, quality or regulatory, this episode will challenge how you think about training, integrity and performance under pressure.

Leadership isn’t memory. It’s identity.

#Leadership #ClinicalResearch #RegulatoryAffairs #Pharmacovigilance #LifeSciences #ProfessionalDevelopment